Pharmacokinetic/Pharmacodynamic Considerations of Beta-Lactam Antibiotics in Adult Critically Ill Patients

被引:35
|
作者
Masich, Anne M. [1 ]
Heavner, Mojdeh S. [1 ]
Gonzales, Jeffrey P. [1 ]
Claeys, Kimberly C. [1 ]
机构
[1] Univ Maryland, Sch Pharm, Dept Pharm Practice & Sci, Baltimore, MD 21201 USA
关键词
Beta-lactams; Critically ill; Pharmacokinetics; Pharmacodynamics; Renal replacement therapy; Extracorporeal membrane oxygenation; EXTRACORPOREAL MEMBRANE-OXYGENATION; RENAL REPLACEMENT THERAPY; CARE-UNIT PATIENTS; CONTINUOUS-INFUSION; SEVERE SEPSIS; POPULATION PHARMACOKINETICS; PIPERACILLIN-TAZOBACTAM; ANTIMICROBIAL THERAPY; PROLONGED INFUSION; DOSING SIMULATIONS;
D O I
10.1007/s11908-018-0613-1
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose of Review Beta-lactam antibiotics are commonly prescribed in critically ill patients for a variety of infectious conditions. Our understanding of how critical illness alters beta-lactam pharmacokinetics/pharmacodynamics (PK/PD) is rapidly evolving. Recent Findings There is a growing body of literature in adult patients demonstrating that physiological alterations occurring in critically ill patients may limit our ability to optimally dose beta-lactam antibiotics to reach these PK/PD targets. These alterations include changes in volume of distribution and renal clearance with multiple, often overlapping causative pathways, including hypoalbuminemia, renal replacement therapy, and extracorporeal membrane oxygenation. Strategies to overcome these PK alterations include extended infusions and therapeutic drug monitoring. Combined data has demonstrated a possible survival benefit associated with extending beta-lactam infusions in critically ill adult patients. Summary This review highlights research on physiological derangements affecting beta-lactam concentrations and strategies to optimize beta-lactam PK/PD in critically ill adults.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] BETA-LACTAM ANTIBIOTICS
    DUNN, GL
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, 1985, 20 : 127 - 135
  • [42] BETA-LACTAM ANTIBIOTICS
    WALSH, TF
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, 1988, 23 : 121 - 131
  • [43] PHARMACOKINETIC STUDY OF BETA-LACTAM ANTIBIOTICS IN BRONCHIAL-SECRETIONS
    BERGOGNEBEREZIN, E
    MOREL, C
    BENARD, Y
    BERTHELOT, G
    KAFE, H
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 1978, : 267 - 272
  • [44] Interindividual variability in plasma levels of beta-lactam antibiotics in critically ill patients with or without continuous renal replacement therapy
    Eliasson, E.
    Giske, C.
    Petersson, J.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 : S12 - S12
  • [45] Pharmacokinetic/pharmacodynamic considerations for the optimization of antimicrobial delivery in the critically ill
    Tsai, Danny
    Lipman, Jeffrey
    Roberts, Jason A.
    CURRENT OPINION IN CRITICAL CARE, 2015, 21 (05) : 412 - 420
  • [46] Target attainment of beta-lactam antibiotics and ciprofloxacin in critically ill patients and its association with 28-day mortality
    Drager, Sarah
    Ewoldt, Tim M. J.
    Abdulla, Alan
    Rietdijk, Wim J. R.
    Verkaik, Nelianne J.
    van Vliet, Peter
    Purmer, Ilse M.
    Osthoff, Michael
    Koch, Birgit C. P.
    Endeman, Henrik
    JOURNAL OF CRITICAL CARE, 2025, 85
  • [47] Health Care Costs of Target Attainment for Beta-Lactam Antibiotics in Critically Ill Patients: A Retrospective Analysis of the EXPAT Study
    Ewoldt, Tim M. J.
    Abdulla, Alan
    Hunfeld, Nicole G. M.
    Muller, Anouk E.
    Gommers, Diederik
    Polinder, Suzanne
    Koch, Birgit C. P.
    Endeman, Henrik
    THERAPEUTIC DRUG MONITORING, 2022, 44 (01) : 224 - 229
  • [48] Pharmacokinetic considerations in critically ill patients
    Escobar, Leslie
    Nella Gai, Maria
    Regueira, Tomas
    Andresen, Max
    REVISTA MEDICA DE CHILE, 2012, 140 (06) : 780 - 788
  • [49] Pharmacodynamic Thresholds for Beta-Lactam Antibiotics: A Story of Mouse Versus Man
    Berry, Angela, V
    Kuti, Joseph L.
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [50] THERAPEUTIC CONSIDERATIONS IN USING COMBINATIONS OF NEWER BETA-LACTAM ANTIBIOTICS
    BARRIERE, SL
    CLINICAL PHARMACY, 1986, 5 (01): : 24 - 33